Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 8/20 | 0.68 |
| ▸ | BACE1 | P56817 | 8/20 | 0.68 |
| ▸ | EGFR | P00533 | 3/20 | 0.64 |
| ▸ | CSF1R | P07333 | 1/20 | 0.62 |
| ▸ | AURKA | O14965 | 4/20 | 0.62 |
| ▸ | INSR | P06213 | 1/20 | 0.62 |
| ▸ | IGF1R | P08069 | 1/20 | 0.62 |
| ▸ | CDK4 | P11802 | 1/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.62 |
| ▸ | HTR7 | P34969 | 1/20 | 0.62 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.61 |
| ▸ | KIT | P10721 | 2/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14407961 | 0.91 | HTR7 (0.68) | ACHEBACE1EGFRCSF1RAURKA | |
| SCHEMBL4399140 | 0.85 | HTR7 (0.64) | ACHEBACE1EGFRCSF1RAURKA | |
| SCHEMBL25686067 | 0.84 | ACHE (0.57) | ACHEBACE1EGFRAURKAHTR7 | |
| SCHEMBL25686047 | 0.83 | ACHE (0.53) | ACHEBACE1EGFRCSF1RAURKA | |
| SCHEMBL11882354 | 0.82 | ACHE (0.88) | ACHEBACE1AURKAPDE10A | |
| SCHEMBL4119501 | 0.82 | ACHE (0.59) | ACHEBACE1EGFRCSF1RAURKA | |
| SCHEMBL4761451 | 0.81 | ACHE (0.67) | ACHEBACE1EGFRCSF1RHTR7 | |
| SCHEMBL20771414 | 0.80 | EGFR (0.57) | ACHEBACE1EGFRCSF1RAURKA | |
| SCHEMBL23721410 | 0.80 | ACHE (0.75) | ACHEBACE1EGFRAURKAHTR7 | |
| Hydrochloric Acid SCHEMBL4760523 | 0.80 | ACHE (0.66) | ACHEBACE1EGFRCSF1RHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | claimed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE12, PDE10A | ACHE 66/4885BACE1 707/4885EGFR 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.